Celgene Corp (CELG)

134.31
NASDAQ : Health Care
Prev Close 133.68
Day Low/High 131.72 / 134.56
52 Wk Low/High 94.42 / 135.18
Avg Volume 3.80M
Exchange NASDAQ
Shares Outstanding 780.82M
Market Cap 104.38B
EPS 2.60
P/E Ratio 50.26
Div & Yield N.A. (N.A)

Latest News

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

Celebrated Photographer Martin Schoeller Shines A Light On People With Psoriatic Disease Including Olympic Swimmer And Author Dara Torres As Part Of Celgene's SHOW MORE OF YOU Campaign

Award-winning portrait photographer Martin Schoeller along with 12-time Olympic medalist and New York Times best-selling author Dara Torres and others with psoriatic disease have come together for the SHOW MORE OF YOU...

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.

Celgene Is Headed Much Higher Even After a Monster Breakout

Celgene Is Headed Much Higher Even After a Monster Breakout

Biotechs are hot.

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

Doug Kass shares his thoughts on Apple, Google and Starbucks.

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Phase 2a Safety And Efficacy Data Support Further Development Of Oral CC-220 In Patients With Lupus

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company's investigational, oral...

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Remember the Rules of the Road

Remember the Rules of the Road

Diversification is the only risk management strategy that will work consistently.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Updated Data From Phase 1 Trial Of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses And Duration Of Response In Patients With Relapsed Or Refractory AML And An IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral...

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.

Bluebird Bio And Celgene Corporation Announce Updated Clinical Results From Ongoing First-in-Human Multicenter Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

bluebird bio, Inc. (NASDAQ:BLUE), and Celgene Corporation (NASDAQ:CELG) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell...

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

100% response rate with zero relapses are the latest update from Bluebird's BB2121 study in multiple myeloma patients.

Here's Why This Top Money Manager Is Now Short Banks Like Bank of America and JP Morgan

Here's Why This Top Money Manager Is Now Short Banks Like Bank of America and JP Morgan

This top mind also shares his thoughts on the shape of the market.

Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog

Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog

Jim Cramer discusses Lululemon and also mentions that the rally is earning some trust.

Unsexy Celgene, Toll Brothers Turn Me On

Unsexy Celgene, Toll Brothers Turn Me On

The two aren't among today's hot names, but are solid long-term growth plays.

Cramer: Rally Is Earning Some Trust

Cramer: Rally Is Earning Some Trust

The market rally broadened out nicely today.

Celgene And Acceleron Complete Target Enrollment In The MEDALIST And BELIEVE Phase 3 Studies Of Luspatercept In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIST and BELIEVE Phase 3 studies of luspatercept in patients with...

Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity

Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity

I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.